Provided by Tiger Trade Technology Pte. Ltd.

Zevra Therapeutics

12.30
+0.24001.99%
Post-market: 12.20-0.0998-0.81%19:54 EDT
Volume:1.35M
Turnover:16.49M
Market Cap:727.11M
PE:12.81
High:12.39
Open:12.07
Low:12.04
Close:12.06
52wk High:15.04
52wk Low:7.16
Shares:59.11M
Float Shares:53.86M
Volume Ratio:1.85
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9602
EPS(LYR):1.35
ROE:34.80%
ROA:8.74%
PB:3.34
PE(LYR):9.11

Loading ...

Zevra Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Reuters
·
Aug 04

Zevra Therapeutics Inc Expected to Post Earnings of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Zevra Publishes Four-Year Real-World U.S. Early Access Data on Miplyffa in Niemann-Pick Disease Type C

Reuters
·
Aug 03

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

Reuters
·
Jul 27

Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim

TIPRANKS
·
Jul 27

Zevra Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 27

Zevra Therapeutics Inc : Canaccord Genuity Cuts Target Price to $20 from $29

THOMSON REUTERS
·
Jul 27

Zevra Therapeutics (ZVRA) Is Down 25.4% After EMA Rejects Arimoclomol MAA In NPC Re-Examination Bid

Simply Wall St.
·
Jul 27

Zevra Therapeutics Down over 24%, on Pace for Largest Percent Decrease Since March 2021

Dow Jones
·
Jul 25

Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 25

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

Benzinga_recent_news
·
Jul 25

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24

EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright

TIPRANKS
·
Jul 24

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Roche Holding AG (OtherRHHVF) and Quest Diagnostics (DGX)

TIPRANKS
·
Jul 24

Zevra Therapeutics Shares Sink After Receiving Regulatory Blow

Dow Jones
·
Jul 24

Zevra Tanks After EU Panel's Negative Opinion on Rare Disease Drug

Reuters
·
Jul 24

Zevra Therapeutics Shares Down 29.9% Premarket After EU Panel Adopts Negative Opinion on Co's Rare Disease Drug Application

THOMSON REUTERS
·
Jul 24

Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA

TIPRANKS
·
Jul 24

EMA Panel Issues Negative Opinion on Zevra Arimoclomol EU Marketing Application for Niemann-pick Disease Type C

Reuters
·
Jul 24

Zevra Therapeutics - to Request Re-examination of Chmp Opinion on Arimoclomol

THOMSON REUTERS
·
Jul 24